Press Releases

Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study

Click here to download full press release Oxford, UK – 13 June 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, today announces positive top-line results from a two-year...

View details

Notice of Interim Results

Oxford, UK – 3 June 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, will be announcing its interim results for the six months ended 30 June 2014 on...

View details

Interim management statement

May 2014 Interim Management Statement Oxford, UK – 19 May 2014: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a clinical-stage specialty biopharmaceutical company, today publishes its interim management statement for the period from...

View details

Circassia Appoints Paul R Edick to its Board of Directors

OXFORD, UK – 17 October 2013 – Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced the appointment of Paul R Edick to its Board.  Mr Edick is currently CEO of...

View details

Circassia’s Rapid Grass Allergy Treatment Achieves Significant Symptom Reduction During Hay Fever Season

OXFORD, UK – 1 October 2013 – Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced successful results from a large phase II clinical study of its ToleroMune® grass allergy treatment...

View details

Circassia Appoints Dr Francesco Granata as Chairman

OXFORD, UK – 25 September 2013 – Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced the appointment of Dr Francesco Granata as Non-Executive Chairman.  Dr Granata is Executive in Residence...

View details

Circassia’s Short-Course House Dust Mite Allergy Treatment Achieves Significant Long-Term Symptom Reduction

OXFORD, UK – 12 September 2013 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful results from a phase II clinical study of its house dust mite allergy treatment (House Dust...

View details

Circassia Initiates Proof-of-Principle Clinical Study for Novel Psoriasis Treatment

Circassia Ltd today announced that it has initiated a proof-of-principle clinical study of its novel topical psoriasis treatment, PAP-1. The phase Ib trial is designed to compare the efficacy of PAP-1 with the marketed psoriasis...

View details

Circassia’s ToleroMune Cat Allergy Treatment Maintains Symptom Improvement Two Years After Start of Short-Course Therapy

OXFORD, UK and SAN ANTONIO, USA – 25 February 2013 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course...

View details

Circassia Receives Outstanding Abstract Awards at 2012 World Allergy Organization International Scientific Conference

OXFORD, UK – 10th December 2012 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the receipt of two Outstanding Abstract Awards at the 2012 World Allergy Organization International Scientific Conference (WISC)....

View details